223:
442:
29:
394:
Parker MH, Smith-Swintosky VL, McComsey DF, Huang Y, Brenneman D, Klein B, et al. (December 2009). "Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzothien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies".
456:
497:
Lin R, Weaner LE, Hoerr DC, Salter R, Gong Y (January 2013). "Expeditious syntheses of stable and radioactive isotope-labeled anticonvulsant agent, JNJ-26990990, and its metabolites".
293:
548:
437:, "Preparation of benzo-fused heteroaryl sulfamide derivatives for the treatment of epilepsy and related disorders", issued 2006-03-02, assigned to
460:
328:. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's
60:
142:
202:
341:
543:
538:
348:
355:
430:
191:
438:
321:
457:"JNJ 26990990 Johnson & Johnson developing anticonvulsant Johnson & Johnson preclinical data"
218:
553:
317:
77:
434:
329:
171:
514:
412:
131:
506:
479:
404:
359:
337:
239:
86:
151:
222:
314:
532:
111:
371:
333:
483:
325:
278:
122:
20:
518:
416:
28:
97:
510:
408:
182:
162:
459:. R & D Focus Drug News. September 22, 2008. Archived from
474:
Fischer J, Ganellin CR (2010). "Chapter 2. Standalone Drugs".
207:
332:
inhibition. It also has potential use in the treatment of
499:
Journal of
Labelled Compounds & Radiopharmaceuticals
358:
of JNJ-26990990 have also been prepared to support its
300:
324:
as a second-generation follow-up to the marketed drug
277:
238:
233:
201:
181:
161:
141:
121:
96:
76:
51:
40:
35:
110:
85:
8:
354:Metabolites and radioactive isotope-labeled
19:
221:
130:
27:
150:
549:Drugs developed by Johnson & Johnson
383:
217:
65:
18:
389:
387:
190:
170:
7:
101:
47:-((Benzothien-3-yl)methyl)sulfamide
14:
476:Analogue-Based Drug Discovery II
256:
250:
16:Experimental anticonvulsant drug
320:currently under development by
397:Journal of Medicinal Chemistry
268:
262:
244:
1:
433:, Parker MH, Reitz AB,
570:
234:Chemical and physical data
484:10.1002/9783527630035.ch2
290:
56:
26:
431:WO patent 2006023861
349:phase II clinical trials
439:Janssen Pharmaceutica
347:JNJ-26990990 entered
322:Janssen Pharmaceutica
463:on October 12, 2012.
313:is a broad-spectrum
68:3--1-benzothiophene
23:
330:carbonic anhydrase
511:10.1002/jlcr.3013
409:10.1021/jm801432r
403:(23): 7528–7536.
351:in October 2007.
334:inflammatory pain
308:
307:
203:CompTox Dashboard
561:
523:
522:
494:
488:
487:
471:
465:
464:
453:
447:
446:
445:
441:
427:
421:
420:
391:
338:neuropathic pain
304:
303:
296:
285:
270:
264:
258:
252:
246:
226:
225:
211:
209:
194:
174:
154:
134:
114:
104:
103:
89:
31:
24:
22:
569:
568:
564:
563:
562:
560:
559:
558:
544:Benzothiophenes
539:Anticonvulsants
529:
528:
527:
526:
496:
495:
491:
473:
472:
468:
455:
454:
450:
443:
429:
428:
424:
393:
392:
385:
380:
368:
299:
297:
294:(what is this?)
291:
283:
273:
267:
261:
255:
249:
229:
205:
197:
177:
157:
137:
117:
100:
92:
72:
69:
64:
63:
17:
12:
11:
5:
567:
565:
557:
556:
551:
546:
541:
531:
530:
525:
524:
489:
466:
448:
422:
382:
381:
379:
376:
375:
374:
367:
364:
315:anticonvulsant
306:
305:
288:
287:
281:
275:
274:
271:
265:
259:
253:
247:
242:
236:
235:
231:
230:
228:
227:
219:DTXSID20470625
214:
212:
199:
198:
196:
195:
187:
185:
179:
178:
176:
175:
167:
165:
159:
158:
156:
155:
147:
145:
139:
138:
136:
135:
127:
125:
119:
118:
116:
115:
107:
105:
94:
93:
91:
90:
82:
80:
74:
73:
71:
70:
67:
59:
58:
57:
54:
53:
49:
48:
42:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
566:
555:
552:
550:
547:
545:
542:
540:
537:
536:
534:
520:
516:
512:
508:
504:
500:
493:
490:
485:
481:
477:
470:
467:
462:
458:
452:
449:
440:
436:
432:
426:
423:
418:
414:
410:
406:
402:
398:
390:
388:
384:
377:
373:
370:
369:
365:
363:
361:
357:
352:
350:
345:
343:
339:
335:
331:
327:
323:
319:
316:
312:
302:
295:
289:
282:
280:
276:
243:
241:
237:
232:
224:
220:
216:
215:
213:
204:
200:
193:
189:
188:
186:
184:
180:
173:
169:
168:
166:
164:
160:
153:
149:
148:
146:
144:
140:
133:
129:
128:
126:
124:
120:
113:
109:
108:
106:
99:
95:
88:
84:
83:
81:
79:
75:
66:
62:
55:
50:
46:
43:
39:
36:Clinical data
34:
30:
25:
505:(1): 22–26.
502:
498:
492:
475:
469:
461:the original
451:
435:Maryanoff BE
425:
400:
396:
372:JNJ-26489112
353:
346:
311:JNJ-26990990
310:
309:
298:
292:
192:ChEMBL466517
172:CHEBI:580267
44:
21:JNJ-26990990
360:development
356:derivatives
286: g·mol
87:877316-38-6
52:Identifiers
41:Other names
554:Sulfamides
533:Categories
378:References
342:depression
326:topiramate
279:Molar mass
152:QFG58Y96EP
123:ChemSpider
78:CAS Number
61:IUPAC name
519:24285137
417:19388676
366:See also
301:(verify)
112:11687376
240:Formula
132:9862103
98:PubChem
517:
444:
415:
340:, and
284:242.31
183:ChEMBL
163:ChEBI
515:PMID
413:PMID
318:drug
143:UNII
507:doi
480:doi
405:doi
208:EPA
102:CID
535::
513:.
503:56
501:.
478:.
411:.
401:52
399:.
386:^
362:.
344:.
336:,
254:10
521:.
509::
486:.
482::
419:.
407::
272:2
269:S
266:2
263:O
260:2
257:N
251:H
248:9
245:C
210:)
206:(
45:N
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
